To provide long term capital growth.
Name | % Net Assets |
---|---|
Royal Dutch Shell | 9.7% |
BP | 9.7% |
GlaxoSmithKline | 7.9% |
HSBC | 6.2% |
Vodafone | 5.5% |
AstraZeneca | 5.0% |
AstraZeneca | 4.5% |
Unilever | 4.0% |
BHP Billiton | 3.9% |
BG | 3.9% |
Key | % Net Assets |
---|---|
Royal Dutch Shell | 9.7% |
BP | 9.7% |
GlaxoSmithKline | 7.9% |
HSBC | 6.2% |
Other | 66.5% |
Date | 15-Dec-2017 |
---|---|
NAV | 63.67p |
Currency | GBP |
Change | -0.33p |
% | -0.52% |
YTD change | 63.67p |
YTD % | n/a |
Fund Inception | 01/08/2008 |
---|---|
Fund Manager | Sarah Emly / James Illsley |
TER | 1.68 (31-Jan-2013) |
Minimum Investment | |
---|---|
Initial | £1000 |
Additional | £100 |
Savings | n/a |
Charges | |
---|---|
Initial | 4.25% |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
No risk data available. |
You are here: research